BioCentury
ARTICLE | Company News

Boehringer Ingelheim, Hydra deal

May 4, 2015 7:00 AM UTC

Boehringer partnered with Hydra to identify small molecule inhibitors of transient receptor potential (TRP) ion channels, with a primary focus on treating renal diseases. Boehringer is responsible for...